全球放射性陶瓷市场，按放射性同位素（鎝99、镓68、碘131、碘123、18F、Y-90、橹-177、铜67、铜64等）按最终用户/地区的应用: 竞争、预测、机会 (2027)

预计全球放射治疗市场在预测期内（2023-2027 年）将以惊人的复合年增长率增长。

放射治疗是在成对的诊断成像和治疗剂中使用放射性核素的过程。这是靶向诊断和治疗的系统整合。癌症患病率的增加和具有抗肿瘤作用的可注射放射性药物的日益普及对全球放射治疗市场的增长做出了重大贡献。此外，继续支持研发以跟上当前放射治疗药物创新的势头，从而支持市场的增长。此外，由于我们成功地了解了癌症的潜在生物学以及改进了合成和设计靶向治疗药物的方法，放射治疗药物的临床使用急剧增加。这对市场增长产生了积极影响。

在本报告中，我们分析了全球放射性陶瓷市场，包括整体市场规模、市场份额结构（按放射性同位素、按应用、按最终用户）以及按地区和主要国家/地区的趋势。我们正在调查详细的市场趋势、主要市场促进与製约因素、企业间市场竞争格局、主要企业概况、未来市场增长方向等。

内容

第一章产品概述

第二章分析方法

第 3 章执行摘要

第 4 章 COVID-19 对全球放射治疗市场的影响

第 5 章客户意见

• 对放射治疗的认可
• 癌症患病率：按性别分类
• 癌症患病率：按年龄组
• 癌症患病率：按地区划分
• 使用放射治疗的好处

第6章临床试验分析

第七章专利分析

第 8 章。全球放射治疗市场：未来展望

• 市场规模和预测
  • 货币基础
• 市场份额和预测
  • 按放射性同位素（鎝99、镓68、碘131、碘123、18F、Y-90、橹 (Lu) 177、铜 (Cu) 67、铜 (Cu) 64、其他）
  • 按用途（肿瘤与非肿瘤）
  • 按最终用户（医院/诊所、製药/生物技术公司等）
  • 按地区
  • 按公司（2021 年）
• 产品市场地图

第 9 章北美放射治疗市场展望

• 市场规模和预测
• 市场份额和预测
• 北美：国家/地区分析
  • 美国无线电陶瓷市场前景
  • 墨西哥无线电陶瓷市场前景
  • 加拿大无线电陶瓷市场前景

第 10 章欧洲放射治疗市场展望

• 市场规模和预测
• 市场份额和预测
• 欧洲：国家/地区分析
  • 法国无线电陶瓷市场展望
  • 德国放射治疗市场展望
  • 英国无线电陶瓷市场前景
  • 意大利无线电陶瓷市场前景
  • 西班牙无线电陶瓷市场前景

第 11 章亚太放射治疗市场展望

• 市场规模和预测
• 市场份额和预测
• 亚太地区：国家/地区分析
  • 中国放射性陶瓷市场前景
  • 印度放射治疗市场展望
  • 韩国无线电陶瓷市场展望
  • 日本无线电陶瓷市场前景
  • 澳大利亚放射治疗市场展望

第 12 章南美放射治疗市场展望

• 市场规模和预测
• 市场份额和预测
• 南美洲：国家/地区分析
  • 巴西无线电陶瓷市场前景
  • 阿根廷无线电陶瓷市场前景
  • 哥伦比亚放射治疗市场展望

第 13 章中东和非洲放射治疗市场展望

• 市场规模和预测
• 市场份额和预测
• 中东和非洲：国家/地区分析
  • 南非放射治疗市场展望
  • 沙特阿拉伯无线电陶瓷市场前景
  • 阿拉伯联合酋长国放射治疗市场展望

第 14 章市场动态

• 驱动程序
• 任务

第 15 章市场趋势和发展

第 16 章 SWOT 分析：全球放射治疗市场

第 17 章竞争格局

• TransCode Therapeutics, Inc.
• Curium SAS
• GE Healthcare Inc.
• Bayer AG
• Lantheus Medical Imaging, Inc.
• Novartis AG
• Spectrum Pharmaceuticals, Inc.
• Ipsen S.A.
• Actinium Pharmaceuticals, Inc. (ATNM)
• Nordic Nanovector ASA
• Y-mAbs Therapeutics, Inc.
• Sofie Biosciences, Inc.
• Terumo Corporation
• Sirtex Medical Limited
• Boston Scientific Corporation

第 18 章战略建议

Global radiotheranostics market is anticipated to register growth at an impressive CAGR in the forecast period, 2023-2027. Radiotheranostics is a process that involves the use of radionuclides for paired imaging and therapy agents. It is a systematic integration of targeted diagnostics and therapeutics. The growing prevalence of cancer and the rising adoption of injectable radiopharmaceuticals that have antitumor effects are majorly contributing to the global radiotheranostics market growth. The increasing usage of radiotheranostics in cancer diagnosis and management is providing a thrust to the market. Radiotheranostics have enhanced therapy efficacy, the ability to manage adverse and critical health situations, which results in improved patient outcomes.

Moreover, the recent research and developments in the radiotheranostics field is creating a positive impact on the market growth. For instance, there have been major outcomes in radiotheranostics for prostate cancer and neuroendocrine tumors. Additionally, the regulatory approval of numerous radiotheranostics pairs is expected to boost their adoption for cancer treatments. For instance, the approvals of new radiotheranostics agents such as 177Lu-PSMA-617 and 177Lu-DOTATATE have resulted in the resurgence of research in the field of radiotheranostics and have proliferated the number of clinical trials and testing several other novel radiotheranostics. Furthermore, the continuous support in research and development to keep pace with current momentum in radiotheranostics innovations is supporting the market growth. Additionally, the clinical use of radiotheranostics agents have increased dramatically due to the successful strides that have been made in the understanding of underlying biology of cancer and enhanced methods for synthesizing and designing targeted theragnostic agents. This, in turn, is positively influencing the market growth.

Structural imaging is the most crucial component of staging, diagnosing, and assessing responses in cancer patients. However, patients and healthcare professionals are increasingly seeking non-invasive methods of investigating tumor phenotypes and assessing molecular and functional responses to therapy. Therefore, radiotheranostics, a combination of non-invasive diagnostic imaging with targeted therapy, is widely being implemented. As a result, the global market for radiotheranostics is anticipated to propel at a rapid pace in the coming years.

Market Segmentation

The global radiotheranostics market is segmented by radioisotope, application, end user, competitive landscape, and regional distribution. Based on the radioisotope, the market is differentiated between technetium-99, gallium-68, iodine-131, iodine-123, 18f, y-90, lutetium (lu) 177, copper (cu) 67, copper (cu) 64, and others. By offering the market is fragmented between oncology and non-oncology. The oncology segment is further bifurcated into thyroid cancer, neuroendocrine cancer, hepatocellular carcinoma, multiple myeloma and lymphoma, and other. The non-oncology application segment is further divided between joint infections, arthritis, bone pain, and others. On the basis of end user, the global market is segmented between hospitals & clinics, pharmaceutical & biotechnology companies, and others. The market analysis also studies the regional segmentation to devise regional market segmentation, divided among North America, Europe, Asia Pacific, Middle east and Africa, South America.

Company Profile

TransCode Therapeutics, Inc., Curium SAS, GE Healthcare Inc., Bayer AG, Lantheus Medical, Imaging, Inc., Novartis AG, Spectrum Pharmaceuticals, Inc., Ipsen S.A., Actinium Pharmaceuticals, Inc. (ATNM), Nordic Nanovector ASA, Y-mAbs Therapeutics, Inc., Sofie Biosciences, Inc., Terumo Corporation, Sirtex Medical Limited, and Boston Scientific Corporation are the leading market players responsible for the growth of global radiotheranostics market.

Report Scope:

In this report, global radiotheranostics market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

Global Radiotheranostics Market, By Radioisotope:

• Technetium-99
• Gallium-68
• Iodine-131
• Iodine-123
• 18F
• Y-90
• Lutetium (Lu) 177
• Copper (Cu) 67
• Copper (Cu) 64
• Others

Global Radiotheranostics Market, By Application:

• Oncology
  • Thyroid Cancer
  • Neuroendocrine Cancer
  • Hepatocellular Carcinoma
  • Multiple Myeloma
  • Lymphoma, Others

• Non-Oncology
  • Joint Infections
  • Arthritis
  • Bone Pain
  • Others
  • Global Radiotheranostics Market, By End User:

• Hospitals & Clinics
• Pharmaceutical & Biotechnology Companies
• Others

Global Radiotheranostics Market, By Region:

• North America
  • United States
  • Mexico
  • Canada

• Europe
  • France
  • Germany
  • United Kingdom
  • Italy
  • Spain

• Asia Pacific
  • China
  • India
  • South Korea
  • Japan
  • Australia

• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE

• South America
  • Brazil
  • Argentina
  • Colombia

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in global radiotheranostics market.

Available Customizations:

With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

2. Research Methodology

3. Executive Summary

4. Impact of COVID-19 on Global Radiotheranostics Market

5. Voice of Customer

• 5.1. Radiotheranostics Awareness
• 5.2. Cancer Prevalence, By Gender
• 5.3. Cancer Prevalence, By Age Group
• 5.4. Cancer Prevalence, Region
• 5.5. Benefits of Using Radiotheranostics

6. Clinical Trial Analysis

7. Patent Analysis

8. Global Radiotheranostics Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Radioisotope (Technetium-99, Gallium-68, Iodine-131, Iodine-123, 18F, Y-90, Lutetium (Lu) 177, Copper (Cu) 67, Copper (Cu) 64, Others)
  • 8.2.2. By Application (Oncology v/s Non-Oncology)
    • 8.2.2.1. Oncology Applications (Thyroid Cancer, Neuroendocrine Cancer, Hepatocellular Carcinoma, Multiple Myeloma and Lymphoma, Others)
    • 8.2.2.2. Non-Oncology Applications (Joint Infections, Arthritis, Bone Pain, Others)
  • 8.2.3. By End User (Hospitals & Clinics, Pharmaceutical & Biotechnology Companies, Others)
  • 8.2.4. By Region
  • 8.2.5. By Company (2021)
• 8.3. Product Market Map

9. North America Radiotheranostics Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Radioisotope (Technetium-99, Gallium-68, Iodine-131, Iodine-123, 18F, Y-90, Lutetium (Lu) 177, Copper (Cu) 67, Copper (Cu) 64, Others)
  • 9.2.2. By Application (Oncology v/s Non-Oncology)
    • 9.2.2.1. Oncology Applications (Thyroid Cancer, Neuroendocrine Cancer, Hepatocellular Carcinoma, Multiple Myeloma and Lymphoma, Others)
    • 9.2.2.2. Non-Oncology Applications (Joint Infections, Arthritis, Bone Pain, Others)
  • 9.2.3. By End User (Hospitals & Clinics, Pharmaceutical & Biotechnology Companies, Others)
  • 9.2.4. By Country
• 9.3. North America: Country Analysis
  • 9.3.1. United States Radiotheranostics Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Radioisotope
      • 9.3.1.2.2. By Application
      • 9.3.1.2.3. By End User
  • 9.3.2. Mexico Radiotheranostics Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Radioisotope
      • 9.3.2.2.2. By Application
      • 9.3.2.2.3. By End User
  • 9.3.3. Canada Radiotheranostics Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Radioisotope
      • 9.3.3.2.2. By Application
      • 9.3.3.2.3. By End User

10. Europe Radiotheranostics Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Radioisotope (Technetium-99, Gallium-68, Iodine-131, Iodine-123, 18F, Y-90, Lutetium (Lu) 177, Copper (Cu) 67, Copper (Cu) 64, Others)
  • 10.2.2. By Application (Oncology v/s Non-Oncology)
    • 10.2.2.1. Oncology Applications (Thyroid Cancer, Neuroendocrine Cancer, Hepatocellular Carcinoma, Multiple Myeloma and Lymphoma, Others)
    • 10.2.2.2. Non-Oncology Applications (Joint Infections, Arthritis, Bone Pain, Others)
  • 10.2.3. By End User (Hospitals & Clinics, Pharmaceutical & Biotechnology Companies, Others)
  • 10.2.4. By Country
• 10.3. Europe: Country Analysis
  • 10.3.1. France Radiotheranostics Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Radioisotope
      • 10.3.1.2.2. By Application
      • 10.3.1.2.3. By End User
  • 10.3.2. Germany Radiotheranostics Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Radioisotope
      • 10.3.2.2.2. By Application
      • 10.3.2.2.3. By End User
  • 10.3.3. United Kingdom Radiotheranostics Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Radioisotope
      • 10.3.3.2.2. By Application
      • 10.3.3.2.3. By End User
  • 10.3.4. Italy Radiotheranostics Market Outlook
    • 10.3.4.1. Market Size & Forecast
      • 10.3.4.1.1. By Value
    • 10.3.4.2. Market Share & Forecast
      • 10.3.4.2.1. By Radioisotope
      • 10.3.4.2.2. By Application
      • 10.3.4.2.3. By End User
  • 10.3.5. Spain Radiotheranostics Market Outlook
    • 10.3.5.1. Market Size & Forecast
      • 10.3.5.1.1. By Value
    • 10.3.5.2. Market Share & Forecast
      • 10.3.5.2.1. By Radioisotope
      • 10.3.5.2.2. By Application
      • 10.3.5.2.3. By End User

11. Asia-Pacific Radiotheranostics Market Outlook

• 11.1. Market Size & Forecast
  • 11.1.1. By Value
• 11.2. Market Share & Forecast
  • 11.2.1. By Radioisotope (Technetium-99, Gallium-68, Iodine-131, Iodine-123, 18F, Y-90, Lutetium (Lu) 177, Copper (Cu) 67, Copper (Cu) 64, Others)
  • 11.2.2. By Application (Oncology v/s Non-Oncology)
    • 11.2.2.1. Oncology Applications (Thyroid Cancer, Neuroendocrine Cancer, Hepatocellular Carcinoma, Multiple Myeloma and Lymphoma, Others)
    • 11.2.2.2. Non-Oncology Applications (Joint Infections, Arthritis, Bone Pain, Others)
  • 11.2.3. By End User (Hospitals & Clinics, Pharmaceutical & Biotechnology Companies, Others)
  • 11.2.4. By Country
• 11.3. Asia-Pacific: Country Analysis
  • 11.3.1. China Radiotheranostics Market Outlook
    • 11.3.1.1. Market Size & Forecast
      • 11.3.1.1.1. By Value
    • 11.3.1.2. Market Share & Forecast
      • 11.3.1.2.1. By Radioisotope
      • 11.3.1.2.2. By Application
      • 11.3.1.2.3. By End User
  • 11.3.2. India Radiotheranostics Market Outlook
    • 11.3.2.1. Market Size & Forecast
      • 11.3.2.1.1. By Value
    • 11.3.2.2. Market Share & Forecast
      • 11.3.2.2.1. By Radioisotope
      • 11.3.2.2.2. By Application
      • 11.3.2.2.3. By End User
  • 11.3.3. South Korea Radiotheranostics Market Outlook
    • 11.3.3.1. Market Size & Forecast
      • 11.3.3.1.1. By Value
    • 11.3.3.2. Market Share & Forecast
      • 11.3.3.2.1. By Radioisotope
      • 11.3.3.2.2. By Application
      • 11.3.3.2.3. By End User
  • 11.3.4. Japan Radiotheranostics Market Outlook
    • 11.3.4.1. Market Size & Forecast
      • 11.3.4.1.1. By Value
    • 11.3.4.2. Market Share & Forecast
      • 11.3.4.2.1. By Radioisotope
      • 11.3.4.2.2. By Application
      • 11.3.4.2.3. By End User
  • 11.3.5. Australia Radiotheranostics Market Outlook
    • 11.3.5.1. Market Size & Forecast
      • 11.3.5.1.1. By Value
    • 11.3.5.2. Market Share & Forecast
      • 11.3.5.2.1. By Radioisotope
      • 11.3.5.2.2. By Application
      • 11.3.5.2.3. By End User

12. South America Radiotheranostics Market Outlook

• 12.1. Market Size & Forecast
  • 12.1.1. By Value
• 12.2. Market Share & Forecast
  • 12.2.1. By Radioisotope (Technetium-99, Gallium-68, Iodine-131, Iodine-123, 18F, Y-90, Lutetium (Lu) 177, Copper (Cu) 67, Copper (Cu) 64, Others)
  • 12.2.2. By Application (Oncology v/s Non-Oncology)
    • 12.2.2.1. Oncology Applications (Thyroid Cancer, Neuroendocrine Cancer, Hepatocellular Carcinoma, Multiple Myeloma and Lymphoma, Others)
    • 12.2.2.2. Non-Oncology Applications (Joint Infections, Arthritis, Bone Pain, Others)
  • 12.2.3. By End User (Hospitals & Clinics, Pharmaceutical & Biotechnology Companies, Others)
  • 12.2.4. By Country
• 12.3. South America: Country Analysis
  • 12.3.1. Brazil Radiotheranostics Market Outlook
    • 12.3.1.1. Market Size & Forecast
      • 12.3.1.1.1. By Value
    • 12.3.1.2. Market Share & Forecast
      • 12.3.1.2.1. By Radioisotope
      • 12.3.1.2.2. By Application
      • 12.3.1.2.3. By End User
  • 12.3.2. Argentina Radiotheranostics Market Outlook
    • 12.3.2.1. Market Size & Forecast
      • 12.3.2.1.1. By Value
    • 12.3.2.2. Market Share & Forecast
      • 12.3.2.2.1. By Radioisotope
      • 12.3.2.2.2. By Application
      • 12.3.2.2.3. By End User
  • 12.3.3. Colombia Radiotheranostics Market Outlook
    • 12.3.3.1. Market Size & Forecast
      • 12.3.3.1.1. By Value
    • 12.3.3.2. Market Share & Forecast
      • 12.3.3.2.1. By Radioisotope
      • 12.3.3.2.2. By Application
      • 12.3.3.2.3. By End User

13. Middle East and Africa Radiotheranostics Market Outlook

• 13.1. Market Size & Forecast
  • 13.1.1. By Value
• 13.2. Market Share & Forecast
  • 13.2.1. By Radioisotope (Technetium-99, Gallium-68, Iodine-131, Iodine-123, 18F, Y-90, Lutetium (Lu) 177, Copper (Cu) 67, Copper (Cu) 64, Others)
  • 13.2.2. By Application (Oncology v/s Non-Oncology)
    • 13.2.2.1. Oncology Applications (Thyroid Cancer, Neuroendocrine Cancer, Hepatocellular Carcinoma, Multiple Myeloma and Lymphoma, Others)
    • 13.2.2.2. Non-Oncology Applications (Joint Infections, Arthritis, Bone Pain, Others)
  • 13.2.3. By End User (Hospitals & Clinics, Pharmaceutical & Biotechnology Companies, Others)
  • 13.2.4. By Country
• 13.3. MEA: Country Analysis
  • 13.3.1. South Africa Radiotheranostics Market Outlook
    • 13.3.1.1. Market Size & Forecast
      • 13.3.1.1.1. By Value
    • 13.3.1.2. Market Share & Forecast
      • 13.3.1.2.1. By Radioisotope
      • 13.3.1.2.2. By Application
      • 13.3.1.2.3. By End User
  • 13.3.2. Saudi Arabia Radiotheranostics Market Outlook
    • 13.3.2.1. Market Size & Forecast
      • 13.3.2.1.1. By Value
    • 13.3.2.2. Market Share & Forecast
      • 13.3.2.2.1. By Radioisotope
      • 13.3.2.2.2. By Application
      • 13.3.2.2.3. By End User
  • 13.3.3. UAE Radiotheranostics Market Outlook
    • 13.3.3.1. Market Size & Forecast
      • 13.3.3.1.1. By Value
    • 13.3.3.2. Market Share & Forecast
      • 13.3.3.2.1. By Radioisotope
      • 13.3.3.2.2. By Application
      • 13.3.3.2.3. By End User

14. Market Dynamics

• 14.1. Drivers
• 14.2. Challenges

15. Market Trends & Developments

16. SWOT Analysis: Global Radiotheranostics Market

17. Competitive Landscape (Inclusive of SWOT Analysis of Players Profiled)

• 17.1. TransCode Therapeutics, Inc.
• 17.2. Curium SAS
• 17.3. GE Healthcare Inc.
• 17.4. Bayer AG
• 17.5. Lantheus Medical Imaging, Inc.
• 17.6. Novartis AG
• 17.7. Spectrum Pharmaceuticals, Inc.
• 17.8. Ipsen S.A.
• 17.9. Actinium Pharmaceuticals, Inc. (ATNM)
• 17.10. Nordic Nanovector ASA
• 17.11. Y-mAbs Therapeutics, Inc.
• 17.12. Sofie Biosciences, Inc.
• 17.13. Terumo Corporation
• 17.14. Sirtex Medical Limited
• 17.15. Boston Scientific Corporation

18. Strategic Recommendations

(Note: The companies list can be customized based on the client requirements.)